COMMUNIQUÉS West-GlobeNewswire

BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
28/04/2026
- New national campaign encourages recognition of ATTR-CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE [...]
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
28/04/2026
Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK [...]
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
28/04/2026
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May 12, 2026, and will [...]
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
28/04/2026
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced [...]
Juniper Biosciences Announces Strategic Collaboration with leading global cancer center on F-MISO (JBS-003): A First-in-Class Precision Diagnostic Poised to Revolutionize Head and Neck Cancer Treatment
28/04/2026
BRIDGEWATER, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Juniper Biosciences today announced a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of JBS-003 (18F- [...]
KFSH Awards Innovation Challenge Winners at C3 Davos of Healthcare™ Silicon Valley Summit
28/04/2026
SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH), a Global Strategic Partner at the C3 Davos of Healthcare™ Silicon Valley Summit, awarded the winners of [...]
Dr. Petros Kotsidis: KFSH Positions AI as a Scalable Model for Real-World Healthcare Innovation
28/04/2026
SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Dr. Petros Kotsidis, Chief Digital Officer at King Faisal Specialist Hospital & Research Centre (KFSH), said the hospital is adopting a system-level approach to [...]
Dr. Björn Zoëga: Scaling Integrated Digital Systems Will Define the Future of Healthcare
28/04/2026
SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Dr. Björn Zoëga, CEO of King Faisal Specialist Hospital & Research Centre Riyadh (KFSH), said the future of healthcare will be defined not by innovation itself, [...]
Yinuo Chen, founder of three major Fertility centers—Tulip, ONELIFE, and Sino—was invited to participate in the Shanghai Medical Exhibition
28/04/2026
BISHKEK, Kyrgyzstan, April 28, 2026 (GLOBE NEWSWIRE) -- Yinuo Chen, founder of three major fertility centers—Kyrgyzstan Tulip, Thailand ONELIFE, and Georgia Sino—was invited to participate in the 2026 Shanghai [...]
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
28/04/2026
OCTOPOD-IP is being conducted to investigate intraperitoneal (IP) administration of THEO-260 in women with advanced platinum-resistant ovarian cancer Recruitment on track in OCTOPOD-IV, a Phase 1/2a multi-centre, multi- [...]
Reacta Healthcare Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board
28/04/2026
DEESIDE, United Kingdom, April 28, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today [...]
Transactions in connection with share buy-back program
28/04/2026
Company announcement no. 12 - 26 28 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Clariane annonce l’offre de 230 millions d’euros d’obligations senior additionnelles en vue de refinancer ses obligations hybrides vertes perpetuelles
28/04/2026
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS D’AMÉRIQUE, AU CANADA, AU JAPON OU EN AUSTRALIE, OU DANS TOUTE AUTRE JURIDICTION OU IL EST ILLÉGAL DE DIFFUSER, DE PUBLIER OU DE [...]
Holivita Launches a New Platform, Offering a Human-Centric Blueprint for Health Through AI and Your DNA
28/04/2026
DUBAI, United Arab Emirates, April 28, 2026 (GLOBE NEWSWIRE) -- Holivita , a forward-thinking med-tech company, announces the launch of its platform designed to support everyday health and self-care. “Health should no [...]
Clariane has launched a proposed offering of €230 million of additional senior notes to refinance its hybrid green perpetual bonds
28/04/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO Clariane has [...]
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
28/04/2026
Company announcement – No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in [...]
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
28/04/2026
Pratteln, Switzerland, April 28, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Board of Directors of the Italian Medicines Agency, AIFA, has approved the reimbursement of AGAMREE® (vamorolone) for the [...]
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
28/04/2026
Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and additional early overall [...]
Castle Rock Hormone Health Announces National Franchise Launch with Franchise Sidekick Amid Growing Demand for Longevity Medicine
28/04/2026
Castle Rock Hormone Health launches a national franchise program with Franchise Sidekick, targeting 100–250 new clinics in 2026 to meet rising demand for longevity-focused, cash-pay hormone and preventive health [...]

Pages